| 贝伐珠单抗在非小细胞肺癌中应用的研究现状 |
| |
| 引用本文： | 陈筱玲. 贝伐珠单抗在非小细胞肺癌中应用的研究现状[J]. 中国肿瘤临床, 2011, 38(12): 747-750. DOI: 10.3969/j.issn.1000-8179.2011.12.016 |
| |
| 作者姓名： | 陈筱玲 |
| |
| 作者单位： | 北京大学临床肿瘤学院,北京肿瘤医院暨北京市肿瘤防治研究所,恶性肿瘤发病机制及转化研究教育部重点实验室,门诊化疗病房(北京市100142) |
| |
| 摘 要： | 目前非小细胞肺癌化疗疗效已经达平台期，亟需寻找新的方法提高疗效。贝伐珠单抗是一种重组抗VEGF单克隆抗体，是首个证实与化疗联合可提高晚期NSCLC 患者生存的靶向治疗药物。近年来许多关于贝伐珠单抗在NSCLC 一线、二线、辅助、新辅助治疗、联合放化疗，安全性及预测标志物的临床研究，现将其研究现状做一综述。
|
| 关 键 词： | 贝伐珠单抗 非小细胞肺癌 有效性 安全性 预测因子 |
| 收稿时间： | 2011-03-09 |
Current Indication of Bevacizumab Treatment for Non-Small Cell Lung Cancer |
| |
| Xiaoling CHEN. Current Indication of Bevacizumab Treatment for Non-Small Cell Lung Cancer[J]. Chinese Journal of Clinical Oncology, 2011, 38(12): 747-750. DOI: 10.3969/j.issn.1000-8179.2011.12.016 |
| |
| Authors: | Xiaoling CHEN |
| |
| Affiliation: | Peking University School of Oncology, Beijing Cancer Hospital and Institute, Key Laboratory of Carcinogenesis and Translational Re-search (Ministry of Education), Beijing 100142, China |
| |
| Abstract: | At present, chemotherapy for non-small cell lung cancer (NSCLC) has reached a therapeutic plateau; new treatment options are needed to improve efficacy. Bevacizumab is a vascular endothelial growth factor monoclonal antibody. It is the first targeted therapy confirmed to improve the chemotherapy survival in advanced NSCLC. Many clinical studies about bevacizumab as first-line, second-line, adjuvant, and neoadjuvant treatments with chemoradiation are ongoing. The article reviews the current indications for beva -cizumab. |
| |
| Keywords: | |
| 本文献已被 万方数据 等数据库收录！ |
| 点击此处可从《中国肿瘤临床》浏览原始摘要信息 |
|
点击此处可从《中国肿瘤临床》下载全文 |
